# Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Study · id `cardio:ct-nct05593575` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05593575](<https://clinicaltrials.gov/study/NCT05593575>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05593575

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

## Technical summary

Registry record NCT05593575. Randomized; double masking; primary purpose treatment. Start 2023-03-22 (actual); primary completion 2024-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 305 participants (enrolled count; ClinicalTrials.gov record NCT05593575, source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)
- Started: 2023-03-22 (actual) (ClinicalTrials.gov record NCT05593575, source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (actual) (ClinicalTrials.gov record NCT05593575, source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)
- Completion: 2024-12-31 (actual) (ClinicalTrials.gov record NCT05593575, source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05593575, source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05593575-2025-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
- Condition: Diabetic Kidney Disease
- Intervention (Drug): SPH3127+SPH3127matching placebo+valsartan matching placebo
- Intervention (Drug): SPH3127+SPH3127matching placebo+valsartan matching placebo
- Intervention (Drug): SPH3127+valsartan matching placebo
- Intervention (Drug): SPH3127 matching placebo+valsartan
- Lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd (`cardio:org-shanghai-pharmaceuticals-holding-co-ltd`)

## Provenance

Content hash: 69d516062a0782ee142435d9a18ddcd8406f1e8f6fe89677df24a30c6be0ed40
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
